Cancer Research Aziza Shad  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cao, Z.
Right arrow Articles by Ching, L.-M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cao, Z.
Right arrow Articles by Ching, L.-M.
[Cancer Research 61, 1517-1521, February 15, 2001]
© 2001 American Association for Cancer Research


Experimental Therapeutics

Interferon-inducible Protein 10 Induction and Inhibition of Angiogenesis in Vivo by the Antitumor Agent 5,6-Dimethylxanthenone-4-acetic Acid (DMXAA)1

Zhihui Cao, Bruce C Baguley and Lai-Ming Ching2

Auckland Cancer Society Research Centre, University of Auckland School of Medicine, Auckland, New Zealand 1000

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a drug synthesized in this laboratory that halts tumor blood flow and induces tumor hemorrhagic necrosis in transplantable murine tumors, is known to induce the synthesis of antiangiogenic cytokines in vitro. We have measured the induction of mRNA for modulators of angiogenesis in vivo and investigated whether DMXAA may also have an additional antiangiogenic action through the production of these cytokines. The genes for IFN-{alpha} and for interferon-inducible protein 10 (IP-10) were strongly induced in both spleen and Colon 38 tumor tissue after DMXAA treatment, whereas that for IFN-{gamma} was induced in spleen but not in tumor. Expression of mRNA for IFN-ß and for the p35 or the p40 subunits of interleukin 12 was not observed in either tissue. Splenic IP-10 mRNA induction was not a result of IFN-{gamma} production induced with DMXAA because spleen tissue from DMXAA-treated mice that lacked functional IFN-{gamma} receptors expressed similar amounts of IP-10 mRNA as those from wild-type mice. A single i.p. injection of DMXAA (20 mg/kg) was sufficient to reduce fibroblast growth factor-induced endothelial cell invasion of Matrigel implants in athymic nude mice by nearly 100%. The inactive analogue 8-methylxanthenone-4-acetic acid did not up-regulate the genes for IP-10 or IFNs and did not inhibit endothelial cell invasion. Antibodies to IP-10 reversed the inhibition of DMXAA of endothelial cell invasion by 58%; antibodies to tumor necrosis factor-{alpha}, IFN-{gamma}, and IFN-{alpha} reversed inhibition by 7%, 5%, and 0%, respectively. The data support the hypothesis that DMXAA, in addition to antivascular effects mediated by tumor necrosis factor-{alpha}, may have an antiangiogenic effect mediated largely by the induction of IP-10.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
J. Li, M. B. Jameson, B. C. Baguley, R. Pili, and S. D. Baker
Population Pharmacokinetic-Pharmacodynamic Model of the Vascular-Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid in Cancer Patients
Clin. Cancer Res., April 1, 2008; 14(7): 2102 - 2110.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
Z. J. Roberts, N. Goutagny, P.-Y. Perera, H. Kato, H. Kumar, T. Kawai, S. Akira, R. Savan, D. van Echo, K. A. Fitzgerald, et al.
The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis
J. Exp. Med., July 9, 2007; 204(7): 1559 - 1569.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. S. Jassar, E. Suzuki, V. Kapoor, J. Sun, M. B. Silverberg, L. Cheung, M. D. Burdick, R. M. Strieter, L.-M. Ching, L. R. Kaiser, et al.
Activation of Tumor-Associated Macrophages by the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid Induces an Effective CD8+ T-Cell-Mediated Antitumor Immune Response in Murine Models of Lung Cancer and Mesothelioma
Cancer Res., December 15, 2005; 65(24): 11752 - 11761.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Seshadri, J. A. Spernyak, R. Mazurchuk, S. H. Camacho, A. R. Oseroff, R. T. Cheney, and D. A. Bellnier
Tumor Vascular Response to Photodynamic Therapy and the Antivascular Agent 5,6-Dimethylxanthenone-4-Acetic Acid: Implications for Combination Therapy
Clin. Cancer Res., June 1, 2005; 11(11): 4241 - 4250.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. E. Thorpe
Vascular Targeting Agents as Cancer Therapeutics
Clin. Cancer Res., January 15, 2004; 10(2): 415 - 427.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.